Genetic testing offers significant potential for early detection, diagnosis, personalized treatment, and preventive strategies for disability-related diseases. Pharmacies, as accessible healthcare hubs, can play a pivotal role in delivering genetic testing services. However, public acceptance and awareness remain limited, particularly in Saudi Arabia. This study aims to evaluate the public knowledge, perceptions, and acceptance of genetic testing for disability-related diseases in Saudi Arabian pharmacies. A cross-sectional survey was conducted with 475 participants recruited via convenience sampling on social media. Data were collected using a structured questionnaire assessing demographics, knowledge, perception, and acceptance of pharmacy-based genetic testing. Statistical analyses, including descriptive statistics, t -tests, ANOVA, and regression modeling, were performed. While 57.6% of participants reported being somewhat aware of genetic testing, only 9.1% considered themselves very knowledgeable. Perceived benefits included early detection (84.4%) and preventive measures (64.4%). Approximately 42.5% felt comfortable with pharmacy-based genetic testing, but concerns regarding pharmacist expertise (57.7%) and test accuracy (50.7%) were prominent barriers. Acceptance was influenced significantly by age, gender, education level, and healthcare background. Despite moderate awareness and acceptance of genetic testing services in pharmacies, significant barriers remain. Addressing public concerns, improving pharmacist training, and enhancing collaborative care models are essential for successful integration of genetic testing into pharmacy practice.

Lung cancer remains a leading cause of cancer-related mortality worldwide. Cuproptosis, a new form of programmed cell death, is emerging as a key regulator in tumor progression. In this review, we talk about the interplay between cuproptosis, non-coding RNAs (ncRNAs), and epigenetic modifications in lung cancer. We performed an extensive review of recent literature to explore the function of ncRNAs in the regulation of cuproptosis, their effects on tumor microenvironment remodeling, immune response regulation, and drug sensitivity. ncRNAs were found to modulate cuproptosis by influencing copper metabolism, apoptosis, and oxidative stress response. Specific ncRNA signatures possess prognostic biomarker and therapeutic target potential in lung cancer. In addition, ncRNA-mediated epigenetic regulation has significant influence on deciding lung cancer formation and treatment outcome. The integration of non-coding RNAs related to cuproptosis into therapies offers great promise for the improvement of lung cancer prognosis. Further studies are needed to validate these findings and promote their implementation in clinical practice.

Background: People with disabilities face significant barriers to accessing pharmacy services, including physical inaccessibility, communication challenges, and inadequate pharmacist training. These barriers often result in poor healthcare outcomes, which lead to a decline in the provided services. Objective: To explore hospital pharmacists’ experiences, challenges, and suggestions for improving pharmacy services for individuals with disabilities in Saudi Arabia. Methods: A qualitative study was conducted using semistructured interviews with fifteen hospital pharmacists selected through purposive sampling. Participants had to have had at least 5 years of experience and direct interaction with disabled patients. Data were transcribed verbatim and analyzed using thematic analysis to identify recurring themes and insights. An inductive thematic analysis approach was employed. Results: The analysis revealed five key themes: (1) physical inaccessibility of pharmacy infrastructure, (2) communication barriers, (3) training needs, (4) the role of assistive technologies, and (5) proposed service improvements. Technology was recognized as a facilitator, with tools such as Braille medication labels, automated dispensing systems, and mobile health applications identified as potential solutions. Participants also proposed structural modifications, mandatory training programs, and dedicated service pathways to address identified challenges. These findings highlight the importance of a comprehensive approach that integrates infrastructure redesign, targeted training, technological solutions, and inclusive healthcare policies. Conclusion: Improving pharmacy services for individuals with disabilities requires structural, educational, and technological interventions to enhance accessibility, communication, and service delivery. Implications for Research and Practice: The findings of this study provide valuable insights into the barriers faced by individuals with disabilities when accessing pharmacy services and offer actionable recommendations for improvement. From a practical perspective, healthcare institutions should prioritize mandatory disability‐awareness and communication training programs for pharmacists, focusing on skills such as sign language, assistive technology use, and inclusive communication strategies. Structural modifications to pharmacy infrastructure, including lowered counters, wider aisles, and accessible shelving, are essential to ensure physical accessibility. In addition, the integration of assistive technologies, such as Braille labels, voice‐assisted mobile apps, and automated dispensing systems, can help address communication gaps and improve medication adherence. Dedicated service pathways for patients with disabilities can further enhance privacy, reduce waiting times, and ensure personalized care delivery. From a research perspective, future studies should explore the perspectives of patients with disabilities to complement pharmacists’ insights, employ mixed‐methods approaches for a more comprehensive understanding, and conduct longitudinal studies to evaluate the long‐term effectiveness of training programs and technological interventions. Cross‐cultural comparative studies can also help identify universal challenges and region‐specific solutions. By addressing these implications, stakeholders—including healthcare institutions, policymakers, and educators—can collaboratively create a more inclusive, accessible, and equitable pharmacy service environment for individuals with disabilities.

Background: Effective communication between hospital pharmacists and patients with disability is essential to ensure proper usage of prescribed medication, medication safety, and therapeutic outcomes. However, patients with hearing impairments encounter unique challenges that are often overlooked in pharmacy practice. There is limited evidence regarding how hospital pharmacists in Saudi Arabia address communication barriers with this patient group. Objective: To explore the experiences, challenges, and suggestions of hospital pharmacists in Saudi Arabia regarding communication with hearing-impaired patients in pharmacy settings. Methods: A qualitative descriptive study was conducted using an open-ended online survey distributed to hospital pharmacists across Saudi Arabia between April and May 2025. Twenty-six pharmacists responded to eight open-ended questions covering their experiences, training, communication barriers, and institutional support. Responses were analyzed thematically to identify key themes and insights. Results: Six major themes resulted from the analysis: (1) lack of formal training and preparedness, (2) limited direct experience with hearing-impaired patients, (3) communication barriers including time constraints and lack of tools, (4) suggestions for communication aids such as tablets and visual boards, (5) institutional responsibilities for training and infrastructure, and (6) pharmacists’ recommendations for inclusive service improvement. The findings highlight a critical gap in pharmacist training and system-level policies to support disability-inclusive communication in hospital pharmacy practice. Conclusion: Hospital pharmacists in Saudi Arabia reported limited preparedness and suggested various practical solutions, including written communication tools and visual aids. Findings indicate opportunities for structured training and institutional support to enhance inclusive communication.

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is widely prescribed for type 2 diabetes mellitus and chronic weight management. With its growing global use, continuous pharmacovigilance is essential to detect emerging patterns of adverse drug reactions (ADRs). To describe the global ADRs profile of semaglutide using data from the World Health Organization’s (WHO) VigiAccess pharmacovigilance database. A retrospective descriptive analysis was conducted using publicly available ADR data retrieved from the WHO-VigiAccess portal on October 18, 2025. The total number and proportion of ADRs were summarized according to the Medical Dictionary for Regulatory Activities (MedDRA) system organ class (SOC). Demographic information, including age group, sex, geographic region, and reporting year, was reviewed descriptively. A total of 81,770 ADR reports associated with semaglutide were identified. The most frequently reported SOCs were gastrointestinal disorders (28%, n = 42,574), general disorders and administration site conditions (12%, n = 19,200), and injury, poisoning and procedural complications (11%, n = 16,601). Additional categories included nervous system disorders (8%), investigations (7%), and metabolism and nutrition disorders (7%). The majority of ADRs were reported among adults aged 45 to 64 years, with most originating from Europe and the Americas. Annual reporting increased markedly between 2018 and 2025, corresponding with expanded clinical use and obesity-related approvals. Global pharmacovigilance data indicate that semaglutide ADRs are primarily gastrointestinal and systemic in nature, consistent with its known pharmacological effects. Continuous monitoring is warranted to identify emerging safety signals and support optimized patient management as use expands worldwide.